Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness

Anderson, Ian M.; Edwards, John

doi:10.1192/apt.7.3.170

Cited by 20 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 In a systematic review on SSRIs as the first line treatment, Anderson and Edwards reported no difference in sexual dysfunction in the patients taking citalopram, fluoxetine, fluvoxamine and sertraline. 17 In our study, sexual function significantly decreased after treatment with citalopram. Also the results showed that erection, satisfaction, libido and ejaculation decreased significantly after treatment with citalopram.…”

Section: Discussionsupporting

confidence: 51%

Comparison of citalopram and fluoxetine sexual side-effects in male patients referred to psychiatric clinic

Herizchi¹,

Mogaddam²

2016

J Anal Res Clin Med

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 51%

Comparison of citalopram and fluoxetine sexual side-effects in male patients referred to psychiatric clinic

Herizchi¹,

Mogaddam²

2016

J Anal Res Clin Med

View full text Add to dashboard Cite

show abstract

“…However, they included only five trials involving fluvoxamine, and their review is now outdated. The clinical guideline released by the same authors (Anderson and Edwards, 2001) suggested that fluvoxamine was not the best choice of SSRI in routine practice because of relatively high discontinuation rate, but this statement needs to be moderated. It is, therefore, very hard for us to speculate why fluvoxamine is less popular than the other SSRIs (Kadusevicius, et al, 2006;Lawrenson, et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis

et al. 2008

View full text Add to dashboard Cite

Fluvoxamine, one of the oldest selective serotonin reuptaking inhibitors, is commonly prescribed to patients with major depression. Several studies have reviewed the efficacy and tolerability of fluvoxamine for the treatment of major depression. However, these reviews are outdated, have not been systematic and/or suffered from several methodological weaknesses. We conducted a systematic review to synthesize the best available evidence on the efficacy of fluvoxamine for adult patients suffering from major depression in comparison with other active antidepressive agents. Relevant randomized controlled trials were identified through a comprehensive search. The primary outcome was a relative risk of response, and the secondary outcome was a relative risk of remission. Tolerability and side-effect profile were also examined. Fifty-three trials were included. There were no large differences between fluvoxamine and any other antidepressants in terms of efficacy and tolerability. There is evidence of differing side effect profiles, especially when comparing gastrointestinal side effects between fluvoxamine and tricyclics. Clinicians should focus on practically or clinically relevant differences including those in side-effect profiles.

show abstract

“…24 Citalopram and sertraline are among the more specific agents and in vitro studies suggest they are least likely to inhibit these iso-enzymes. A recent survey of rehabilitation consultants and geriatricians in the UK 23 has demonstrated these two agents to be the most common first choice for management of depression following ABI at present.…”

Section: Choice Of Antidepressantmentioning

confidence: 99%

Use of antidepressant medication following acquired brain injury: concise guidance

Turner-Stokes

MacWalter

2005

Clinical Medicine

View full text Add to dashboard Cite

Introduction and aimsAcquired brain injury (ABI) -whether due to stroke, trauma or any other cause -is frequently complicated by depression, which can interfere with rehabilitation, leading to poorer outcomes. The use of antidepressants in the treatment of depression following ABI is increasingly widespread. Because it may not be practical to involve a psychiatrist in all cases, first line management is usually undertaken by general clinicians. However, at present, many people are given antidepressant medication as a matter of routine -often without their knowledge and without any clear treatment plan.The aim of these guidelines is to provide the general physician, GP or other clinician with a safe approach to managing minor to moderate depression in the context of rehabilitation or recovery from ABI, and to identify those individuals who require referral to mental health services.The guidelines focus on the use of antidepressant drugs, but these are by no means the only way to manage depression following ABI, and it is important in any event to consider other contributing factors before reaching for the prescription pad. Alternative interventions may include simple measures to address environmental or other factors which contribute to low mood (such as missing their home and family, or worries about life outside hospital), and non-pharmacological interventions, such as 'talking therapies' , for patients who have the cognitive and communicative abilities to engage successfully.The guidelines have been prepared in accordance with the principles laid down by the AGREE Collaboration (Appraisal of Guidelines for REsearch and Evaluation). 1 A summary of the guideline development process is given in Table 1. Although developed specifically with brain injury in mind, the main principles applied here may also be applicable in other conditions, especially where the person's ability to interact is impaired.I CLINICAL GUIDANCE 268

show abstract

Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness

Cited by 20 publications

References 36 publications

Comparison of citalopram and fluoxetine sexual side-effects in male patients referred to psychiatric clinic

Comparison of citalopram and fluoxetine sexual side-effects in male patients referred to psychiatric clinic

Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis

Use of antidepressant medication following acquired brain injury: concise guidance

Contact Info

Product

Resources

About